Crossmark

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Crossref DOI link: https://doi.org/10.1038/s41586-021-03594-0

Published Online: 2021-05-10

Published Print: 2021-06-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saunders, Kevin O. https://orcid.org/0000-0001-7399-7954
Lee, Esther

Parks, Robert

Martinez, David R.

Li, Dapeng

Chen, Haiyan

Edwards, Robert J. https://orcid.org/0000-0003-4446-1194
Gobeil, Sophie https://orcid.org/0000-0002-0057-2477
Barr, Maggie

Mansouri, Katayoun

Alam, S. Munir

Sutherland, Laura L.

Cai, Fangping

Sanzone, Aja M.

Berry, Madison

Manne, Kartik

Bock, Kevin W. https://orcid.org/0000-0001-9454-0937
Minai, Mahnaz

Nagata, Bianca M.

Kapingidza, Anyway B.

Azoitei, Mihai

Tse, Longping V. https://orcid.org/0000-0001-7582-8396
Scobey, Trevor D.

Spreng, Rachel L. https://orcid.org/0000-0003-1254-0760
Rountree, R. Wes

DeMarco, C. Todd

Denny, Thomas N.

Woods, Christopher W.

Petzold, Elizabeth W.

Tang, Juanjie

Oguin, Thomas H. III

Sempowski, Gregory D.

Gagne, Matthew

Douek, Daniel C.

Tomai, Mark A.

Fox, Christopher B.

Seder, Robert https://orcid.org/0000-0003-3133-0849
Wiehe, Kevin

Weissman, Drew

Pardi, Norbert

Golding, Hana

Khurana, Surender https://orcid.org/0000-0002-0593-7965
Acharya, Priyamvada https://orcid.org/0000-0002-0089-277X
Andersen, Hanne https://orcid.org/0000-0003-1103-9608
Lewis, Mark G.

Moore, Ian N.

Montefiori, David C.

Baric, Ralph S. https://orcid.org/0000-0001-6827-8701
Haynes, Barton F. https://orcid.org/0000-0002-7643-9023
License Information

Text and Data Mining valid from 2021-05-10

Version of Record valid from 2021-05-10
More Information

Article History

Received: 7 February 2021

Accepted: 29 April 2021

First Online: 10 May 2021

Competing interests

: B.F.H. and K.O.S. have filed US patents regarding the nanoparticle vaccine, M.A.T. and the 3M company have US patents filed on 3M052, and C.B.F. and IDRI have filed patents on the formulation of 3M052 and alum. The 3M company had no role in the execution of the study, data collection or data interpretation. D.W. is named on US patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. D.W. and N.P. are also named on a US patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. All other authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below